Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in Relapsing Multiple Sclerosis
NCT06104683Phase 2Withdrawn
- Sponsor
- Loxo Oncology
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pirtobrutinib in relapsing-remitting multiple sclerosis (RRMS), sponsored by Loxo Oncology. Planned start May 2024; status: withdrawn.
02
Drugs
pirtobrutinib
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06104683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104683.